bioRxivCancer BiologyPreprint
Statistical mining of triple-negative breast cancer-specific nanobodies among huge libraries from immunized alpacas
R. Maeda, H. Yamazaki, R. Kobayashi, S. Yamamoto, K. Kasai, A. Imura
Abstract
Breast cancer can be classified into several types according to the expression patterns of human epidermal growth factor receptor 2 (Her2), oestrogen receptor (ER), and progesterone receptor (PgR) proteins. The prognosis of patients with tumors showing low Her2 expression and no ER and PgR expression--categorized as triple-negative breast cancer (TNBC)--is worst among these groups. Due to the lack of specific antibodies for TNBC, curative treatments for TNBC remain limited. Antibodies targeting TNBC have potential as diagnostic and therapeutic tools. Here, we generate a panel of nanobodies targeting TNBC cell lines by immunizing alpacas and subsequently panning the resulting phage libraries with TNBC cell lines. We show that several clones exclusively stain Her2-negative cells in tissues of breast cancer patients, and a few clones stain both Her2-positive and Her2-negative regions in these tissues. These clones can be applied to patient-specific therapies using drug-conjugated antibodies, radiolabelled antibodies, chimaera antigen receptor T cells, or drug delivery components, as well as to TNBC diagnosis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models
D. Kortleve, D. Hammerl, … R. Debets·bioRxiv·Jan 10, 2024
- A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
- Identification of Key Genes Potentially Related to Triple Receptor Negative Breast Cancer by Microarray Analysis
Basavaraj Mallikarjunayya Vastrad, Chanabasayya Mallikarjunayya Vastrad, Iranna Kotturshetti·bioRxiv·Dec 21, 2020
- A comprehensive analysis of immune landscape of Indian triple negative breast cancer
A. Korlimarla, H. PS, … A. Sadanandam·bioRxiv·Mar 6, 2022
- Zr-labeled N4MU01 radioimmunoconjugates as theranostics against nectin-4 positive triple negative breast cancer
H. Babeker, F. N. Njotu, … H. Fonge·bioRxiv·Mar 4, 2024
- Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer
Kaiah M. Fields, Gabriela Terue Rizzo Kodama, … Heide L. Ford·bioRxiv·Oct 22, 2026